+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Cognitive and Memory Enhancer Drugs Market by Product, Application: Global Opportunity Analysis and Industry Forecast, 2021-2030

  • PDF Icon

    Report

  • 270 Pages
  • March 2022
  • Region: Global
  • Allied Market Research
  • ID: 5578244
The global cognitive and memory enhancer drug market was valued at $5,079.86 million in 2020, and is projected to reach $8,689.74 million by 2030, registering a CAGR of 5.5% from 2021 to 2030. Cognitive and memory enhancer drugs, supplements, and other substances are claimed to improve cognitive function, particularly executive functions, attention, memory, creativity, or motivation, in healthy individuals. These drugs include a number of different kinds of substances that can increase mental performance and capable of improving or preserving memory, of potentiating learning, or of preventing cognitive decline or dementia.



The major factors that contribute to the market growth include surge in geriatric population, which is highly prone to neurological disorders such as Alzheimer’s. Moreover, rise in adoption of cognitive drugs, owing to their benefits such as improved physical and mental performance, boosts the market growth. However, ethical issues related with the use of such drugs restrain the growth of this market.

The cognitive and memory enhancer drug market is segmented into product, application, and region. By product, the market is fragmented into Aricept, Exelon, Namenda, Razadyne, Provigil, Ritalin, Adderall, and others. By application, it is segregated into disease treatment, education, sports, and others. Region wise, the cognitive and memory enhancer drug market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The key players operating in the global cognitive and memory enhancer drug market include AbbVie, Alterna Script LLC, Ceretropic, Biogen., Johnson & Johnson, Novartis International AG, Pfizer Inc., Takeda Pharmaceutical Company Ltd., Torrent Pharmaceutical, Inc., and Teva Pharmaceutical Industries Ltd. (Cephalon Inc.).

KEY BENEFITS FOR STAKEHOLDERS

  • The report provides an in-depth analysis of the global cognitive and memory enhancer drug market size along with the current trends and future estimations to elucidate the imminent investment pockets
  • It offers market analysis from 2021 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market
  • A comprehensive analysis on region assists to understand the regional market and facilitate the strategic business planning and determine prevailing opportunities
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global cognitive and memory enhancer drug market

KEY MARKET SEGMENTS


By Product

  • Aricept
  • Exelon
  • Namenda
  • Razadyne
  • Provigill
  • Ritalin
  • Adderall
  • Others

By Application

  • Disease Treatment
  • Education
  • Sports
  • Others

By Region

  • North America
  • US
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

KEY MARKET PLAYERS

  • AbbVie
  • Alterna Script LLC
  • Ceretropic
  • Eisai Co Ltd
  • Johnson & Johnson
  • Novartis International AG
  • Pfizer Inc
  • Takeda Pharmaceutical Company Ltd
  • GlobalMed
  • Teva Pharmaceutical Industries Ltd. (Cephalon Inc)
Frequently Asked Questions about the Global Cognitive and Memory Enhancer Drug Market

What is the estimated value of the Global Cognitive and Memory Enhancer Drug Market?

The Global Cognitive and Memory Enhancer Drug Market was estimated to be valued at $5079.86 million in 2020.

What is the growth rate of the Global Cognitive and Memory Enhancer Drug Market?

The growth rate of the Global Cognitive and Memory Enhancer Drug Market is 5.5%, with an estimated value of $8689.74 million by 2030.

What is the forecasted size of the Global Cognitive and Memory Enhancer Drug Market?

The Global Cognitive and Memory Enhancer Drug Market is estimated to be worth $8689.74 million by 2030.

Who are the key companies in the Global Cognitive and Memory Enhancer Drug Market?

Key companies in the Global Cognitive and Memory Enhancer Drug Market include AbbVie, Alterna Script LLC, Ceretropic, Biogen, Inc., Johnson & Johnson, Novartis International AG, Pfizer Inc., Takeda Pharmaceutical Company Ltd., Torrent Pharmaceuticals and Teva Pharmaceutical Industries Ltd. (Cephalon Inc.)..

Table of Contents

Chapter 1: Introduction
1.1. Report Description
1.2. Key Benefits for Stakeholders
1.3. Key Market Segments
1.4. Research Methodology
1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools and Models
Chapter 2: Executive Summary
2.1. Key Findings of the Study
2.2. Cxo Perspective
Chapter 3: Market Overview
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Winning Strategies
3.2.2. Top Investment Pockets
3.3. Market Share Analysis, 2020
3.4. Market Dynamics
3.4.1. Drivers
3.4.1.1. Rapid Growth of Geriatric Population
3.4.1.2. High Incidence of Neurodegenerative Disorders
3.4.1.3. Benefits of Smart Drugs
3.4.2. Restraint
3.4.2.1. Numerous Ethical Issues
3.4.3. Opportunity
3.4.3.1. Effective Strength of the Drugs
3.4.4. Impact Analyses
3.4. Covid-19 Impact Analysis
Chapter 4: Cognitive and Memory Enhancer Drugs Market, by Product
4.1. Overview
4.1.1. Market Size and Forecast
4.2. Aricept
4.2.1. Key Market Trends, Growth Factors, and Opportunities
4.2.2. Market Size and Forecast, by Region
4.2.3. Market Analysis, by Country
4.3. Exelon
4.3.1. Key Market Trends, Growth Factors, and Opportunities
4.3.2. Market Size and Forecast, by Region
4.3.3. Market Analysis, by Country
4.4. Namenda
4.4.1. Key Market Trends, Growth Factors, and Opportunities
4.4.2. Market Size and Forecast, by Region
4.4.3. Market Analysis, by Country
4.5. Razadyne
4.5.1. Key Market Trends, Growth Factors, and Opportunities
4.5.2. Market Size and Forecast, by Region
4.5.3. Market Analysis, by Country
4.6. Provigil
4.6.1. Key Market Trends, Growth Factors, and Opportunities
4.6.2. Market Size and Forecast, by Region
4.6.3. Market Analysis, by Country
4.7. Ritalin
4.7.1. Key Market Trends, Growth Factors, and Opportunities
4.7.2. Market Size and Forecast, by Region
4.7.3. Market Analysis, by Country
4.8. Adderall
4.8.1. Key Market Trends, Growth Factors, and Opportunities
4.8.2. Market Size and Forecast, by Region
4.8.3. Market Analysis, by Country
4.9. Others
4.9.1. Key Market Trends, Growth Factors, and Opportunities
4.9.2. Market Size and Forecast, by Region
4.9.3. Market Analysis, by Country
Chapter 5: Cognitive and Memory Enhancer Drugs Market, by Application
5.1. Overview
5.1.1. Market Size and Forecast
5.2. Disease Treatment
5.2.1. Market Size and Forecast, by Type
5.2.1.1. Developmental Conditions
5.2.1.1.1. Market Size and Forecast
5.2.1.2. Neurodegenerative Disorders
5.2.1.2.1. Market Size and Forecast
5.2.2. Market Size and Forecast, by Region
5.2.3. Market Analysis, by Country
5.3. Academic Performance
5.3.1. Market Size and Forecast, by Region
5.3.2. Market Analysis, by Country
5.4. Athletic Performance
5.4.1. Market Size and Forecast, by Region
5.4.2. Market Analysis, by Country
5.5. Others
5.5.1. Market Size and Forecast, by Region
5.5.2. Market Analysis, by Country
Chapter 6: Cognitive and Memory Enhancer Drugs Market, by Region
6.1. Overview
6.1.1. Market Size and Forecast
6.2. North America
6.2.1. Key Market Trends, Growth Factors, and Opportunities
6.2.2. North America Market Size and Forecast, by Country
6.2.2.1. U. S.
6.2.2.1.1. U. S. Market Size and Forecast, by Product
6.2.2.1.2. U. S. Market Size and Forecast, by Application
6.2.2.2. Canada
6.2.2.2.1. Canada Market Size and Forecast, by Product
6.2.2.2.2. Canada Market Size and Forecast, by Application
6.2.2.3. Mexico
6.2.2.3.1. Mexico Market Size and Forecast, by Product
6.2.2.3.2. Mexico Market Size and Forecast, by Application
6.2.3. North America Market Size and Forecast, by Product
6.2.4. North America Market Size and Forecast, by Application
6.3. Europe
6.3.1. Key Market Trends, Growth Factors, and Opportunities
6.3.2. Market Size and Forecast, by Country
6.3.2.1. Germany
6.3.2.1.1. Germany Market Size and Forecast, by Product
6.3.2.1.2. Germany Market Size and Forecast, by Application
6.3.2.2. France
6.3.2.2.1. France Market Size and Forecast, by Product
6.3.2.2.2. France Market Size and Forecast, by Application
6.3.2.3. Uk
6.3.2.3.1. Uk Market Size and Forecast, by Product
6.3.2.3.2. Uk Market Size and Forecast, by Application
6.3.2.4. Italy
6.3.2.4.1. Italy Market Size and Forecast, by Product
6.3.2.4.2. Italy Market Size and Forecast, by Application
6.3.2.5. Spain
6.3.2.5.1. Spain Market Size and Forecast, by Product
6.3.2.5.2. Spain Market Size and Forecast, by Application
6.3.2.6. Rest of Europe
6.3.2.6.1. Rest of Europe Market Size and Forecast, by Product
6.3.2.6.2. Rest of Europe Market Size and Forecast, by Application
6.3.3. Europe Market Size and Forecast, by Product
6.3.4. Europe Market Size and Forecast, by Application
6.4. Asia-Pacific
6.4.1. Key Market Trends, Growth Factors, and Opportunities
6.4.2. Market Size and Forecast, by Country
6.4.2.1. Japan
6.4.2.1.1. Japan Market Size and Forecast, by Product
6.4.2.1.2. Japan Market Size and Forecast, by Application
6.4.2.2. China
6.4.2.2.1. China Market Size and Forecast, by Product
6.4.2.2.2. China Market Size and Forecast, by Application
6.4.2.3. India
6.4.2.3.1. India Market Size and Forecast, by Product
6.4.2.3.2. India Market Size and Forecast, by Application
6.4.2.4. Australia
6.4.2.4.1. Australia Market Size and Forecast, by Product
6.4.2.4.2. Australia Market Size and Forecast, by Application
6.4.2.5. South Korea
6.4.2.5.1. South Korea Market Size and Forecast, by Product
6.4.2.5.2. South Korea Market Size and Forecast, by Application
6.4.2.5. Rest of Asia-Pacific
6.4.2.5.1. Rest of Asia-Pacific Market Size and Forecast, by Product
6.4.2.5.2. Rest of Asia-Pacific Market Size and Forecast, by Application
6.4.3. Asia-Pacific Market Size and Forecast, by Product
6.4.4. Asia-Pacific Market Size and Forecast, by Application
6.5. Lamea
6.5.1. Key Market Trends, Growth Factors, and Opportunities
6.5.2. Market Size and Forecast, by Country
6.5.2.1. Brazil
6.5.2.1.1. Brazil Market Size and Forecast, by Product
6.5.2.1.2. Brazil Market Size and Forecast, by Application
6.5.2.2. Saudi Arabia
6.5.2.2.1. Saudi Arabia Market Size and Forecast, by Product
6.5.2.2.2. Saudi Arabia Market Size and Forecast, by Application
6.5.2.3. South Africa
6.5.2.3.1. South Africa Market Size and Forecast, by Product
6.5.2.3.2. South Africa Market Size and Forecast, by Application
6.5.2.4. Rest of LAMEA
6.5.2.4.1. Rest of LAMEA Market Size and Forecast, by Product
6.5.2.4.2. Rest of LAMEA Market Size and Forecast, by Application
6.5.3. Lamea Market Size and Forecast, by Product
6.5.4. Lamea Market Size and Forecast, by Application
Chapter 7: Company Profile
7.1. Allergan plc.
7.1.1. Company Overview
7.1.2. Company Snapshot
7.1.3. Operating Business Segments
7.1.4. Product Portfolio
7.1.5. Business Performance
7.1.6. Key Strategic Moves and Developments
7.2. Alternascript LLC
7.2.1. Company Overview
7.2.2. Company Snapshot
7.2.3. Operating Business Segments
7.2.4. Product Portfolio
7.3. Biogen.
7.3.1. Company Overview
7.3.2. Company Snapshot
7.3.3. Operating Business Segments
7.3.4. Product Portfolio
7.3.5. Business Performance
7.3. Ceretropic
7.3.1. Company Overview
7.3.2. Company Snapshot
7.3.3. Opreating Segmentt
7.3.4. Product Portfolio
7.4. Biogen.
7.4.1. Company Overview
7.4.2. Company Snapshot
7.4.3. Operating Business Segments
7.4.4. Product Portfolio
7.4.5. Business Performance
7.4.6. Key Strategic Moves and Developments
7.5. Johnson & Johnson
7.5.1. Company Overview
7.5.2. Company Snapshot
7.5.3. Operating Business Segments
7.5.4. Product Portfolio
7.5.5. Business Performance
7.5.6. Key Strategic Moves and Developments
7.6. Novartis International AG
7.6.1. Company Overview
7.6.2. Company Snapshot
7.6.3. Operating Business Segments
7.6.4. Product Portfolio
7.6.5. Business Performance
7.6.6. Key Strategic Moves and Developments
7.7. Pfizer Inc.
7.7.1. Company Overview
7.7.2. Company Snapshot
7.7.3. Operating Business Segments
7.7.4. Product Portfolio
7.7.5. Business Performance
7.8. Torrent Pharmaceutical, Inc.
7.8.1. Company Overview
7.8.2. Company Snapshot
7.8.3. Operating Business Segments
7.8.4. Product Portfolio
7.9. Takeda Pharmaceutical Company Ltd.
7.9.1. Company Overview
7.9.2. Company Snapshot
7.9.3. Operating Business Segments
7.9.4. Product Portfolio
7.9.5. Business Performance
7.9.6. Key Strategic Moves and Developments
7.10. Teva Pharmaceutical Industries Ltd. (Cephalon Inc.)
7.10.1. Company Overview
7.10.2. Company Snapshot
7.10.3. Operating Business Segments
7.10.4. Product Portfolio
7.10.5. Business Performance
List of Tables
List of Tables
Table 01. Global Cognitive and Memory Enhancer Drugs Market, by Product, 2020–2030 ($Million)
Table 02. Aricept Market, by Region, 2020–2030 ($Million)
Table 03. Exelon Market, by Region, 2020–2030 ($Million)
Table 04. Namenda Market, by Region, 2020–2030 ($Million)
Table 05. Razadyne Market, by Region, 2020–2030 ($Million)
Table 06. Provigil Market, by Region, 2020–2030 ($Million)
Table 07. Ritalin Market, by Region, 2020–2030 ($Million)
Table 08. Adderall Market, by Region, 2020–2030 ($Million)
Table 09. Others Market, by Region, 2020–2030 ($Million)
Table 10. Global Cognitive and Memory Enhancer Drugs Market, by Application, 2020–2030 ($Million)
Table 11. Effect of the Cognitive and Memory Enhancer Drugs Used for Disease Treatment
Table 12. Cognitive and Memory Enhancer Drugs Market for Disease Treatment, by Type, 2020–2030 ($Million)
Table 13. Cognitive and Memory Enhancer Drugs Market for Disease Treatment, by Region, 2020–2030 ($Million)
Table 14. Cognitive and Memory Enhancer Drugs Market for Academic Performance, by Region, 2020–2030 ($Million)
Table 15. Cognitive and Memory Enhancer Drugs Market for Athletic Performance, by Region, 2020–2030 ($Million)
Table 16. Cognitive and Memory Enhancer Drugs Market for Other Applications, by Region, 2020–2030 ($Million)
Table 17. Cognitive and Memory Enhancer Drugs Market, by Region, 2020–2030 ($Million)
Table 18. North America Cognitive and Memory Enhancer Drugs Market, by Country, 2020–2030 ($Million)
Table 19. U.S Cognitive and Memory Enhancer Drugs Market, by Product, 2020–2030 ($Million)
Table 20. U.S Cognitive and Memory Enhancer Drugs Market, by Product, 2020–2030 ($Million)
Table 21. Canada Cognitive and Memory Enhancer Drugs Market, by Product, 2020–2030 ($Million)
Table 22. Canada Cognitive and Memory Enhancer Drugs Market, by Application, 2020–2030 ($Million)
Table 23. Mexico Cognitive and Memory Enhancer Drugs Market, by Product, 2020–2030 ($Million)
Table 24. Mexico Cognitive and Memory Enhancer Drugs Market, by Application, 2020–2030 ($Million)
Table 25. North America Cognitive and Memory Enhancer Drugs Market, by Product, 2020–2030 ($Million)
Table 26. North America Cognitive and Memory Enhancer Drugs Market, by Application, 2020–2030 ($Million)
Table 28. Europe Cognitive and Memory Enhancer Drugs Market, by Country, 2020–2030 ($Million)
Table 29. Germany Cognitive and Memory Enhancer Drugs Market, by Product, 2020–2030 ($Million)
Table 30. Germany Cognitive and Memory Enhancer Drugs Market, by Product, 2020–2030 ($Million)
Table 31. France Cognitive and Memory Enhancer Drugs Market, by Product, 2020–2030 ($Million)
Table 32. France Cognitive and Memory Enhancer Drugs Market, by Application, 2020–2030 ($Million)
Table 33. Uk Cognitive and Memory Enhancer Drugs Market, by Product, 2020–2030 ($Million)
Table 34. Uk Cognitive and Memory Enhancer Drugs Market, by Application, 2020–2030 ($Million)
Table 35. Italy Cognitive and Memory Enhancer Drugs Market, by Product, 2020–2030 ($Million)
Table 36. Italy Cognitive and Memory Enhancer Drugs Market, by Application, 2020–2030 ($Million)
Table 37. Spain Cognitive and Memory Enhancer Drugs Market, by Product, 2020–2030 ($Million)
Table 38. Spain Cognitive and Memory Enhancer Drugs Market, by Application, 2020–2030 ($Million)
Table 39. Rest of Europe Cognitive and Memory Enhancer Drugs Market, by Product, 2020–2030 ($Million)
Table 40. Rest of Europe Cognitive and Memory Enhancer Drugs Market, by Application, 2020–2030 ($Million)
Table 41. Europe Cognitive and Memory Enhancer Drugs Market, by Product, 2020–2030 ($Million)
Table 42. Europe Cognitive and Memory Enhancer Drugs Market, by Application, 2020–2030 ($Million)
Table 43. Asia-Pacific Cognitive and Memory Enhancer Drugs Market, by Country, 2020–2030 ($Million)
Table 44. Japan Cognitive and Memory Enhancer Drugs Market, by Product, 2020–2030 ($Million)
Table 45. Japan Cognitive and Memory Enhancer Drugs Market, by Application, 2020–2030 ($Million)
Table 46. China Cognitive and Memory Enhancer Drugs Market, by Product, 2020–2030 ($Million)
Table 47. China Cognitive and Memory Enhancer Drugs Market, by Application, 2020–2030 ($Million)
Table 48. India Cognitive and Memory Enhancer Drugs Market, by Product, 2020–2030 ($Million)
Table 49. India Cognitive and Memory Enhancer Drugs Market, by Application, 2020–2030 ($Million)
Table 50. Australia Cognitive and Memory Enhancer Drugs Market, by Product, 2020–2030 ($Million)
Table 51. Australia Cognitive and Memory Enhancer Drugs Market, by Application, 2020–2030 ($Million)
Able 50. South Korea Cognitive and Memory Enhancer Drugs Market, by Product, 2020–2030 ($Million)
Table 51. South Korea Cognitive and Memory Enhancer Drugs Market, by Application, 2020–2030 ($Million)
Table 52. Rest of Asia-Pacific Cognitive and Memory Enhancer Drugs Market, by Product, 2020–2030 ($Million)
Table 53. Rest of Asia-Pacific Cognitive and Memory Enhancer Drugs Market, by Application, 2020–2030 ($Million)
Table 54. Asia-Pacific Cognitive and Memory Enhancer Drugs Market, by Product, 2020–2030 ($Million)
Table 55. Asia-Pacific Cognitive and Memory Enhancer Drugs Market, by Application, 2020–2030 ($Million)
Table 56. Lamea Cognitive and Memory Enhancer Drugs Market, by Country, 2020–2030 ($Million)
Table 57. Brazil Cognitive and Memory Enhancer Drugs Market, by Product, 2020–2030 ($Million)
Table 58. Brazil Cognitive and Memory Enhancer Drugs Market, by Application, 2020–2030 ($Million)
Table 59. Saudi Arabia Cognitive and Memory Enhancer Drugs Market, by Product, 2020–2030 ($Million)
Table 60. Saudi Arabia Cognitive and Memory Enhancer Drugs Market, by Application, 2020–2030 ($Million)
Table 61. South Africa Cognitive and Memory Enhancer Drugs Market, by Product, 2020–2030 ($Million)
Table 62. South Africa Cognitive and Memory Enhancer Drugs Market, by Application, 2020–2030 ($Million)
Table 63. Rest of LAMEA Cognitive and Memory Enhancer Drugs Market, by Product, 2020–2030 ($Million)
Table 64. Rest of LAMEA Cognitive and Memory Enhancer Drugs Market, by Application, 2020–2030 ($Million)
Table 65. Lamea Cognitive and Memory Enhancer Drugs Market, by Product, 2020–2030 ($Million)
Table 66. Lamea Cognitive and Memory Enhancer Drugs Market, by Application, 2020–2030 ($Million)
Table 67. Abbvie: Company Snapshot
Table 68. Abbvie: Operating Segments
Table 69. Abbvie: Product Portfolio
Table 70. Alternascript: Company Snapshot
Table 71. Alternascript: Operating Segments
Table 72. Alternascript: Product Portfolio
Table 73. Biogen: Company Snapshot
Table 74. Biogen: Product Portfolio
Table 75. Ceretropic: Company Snapshot
Table 76. Ceretropic: Operating Segments
Table 77. Ceretropic: Product Portfolio
Table 78. J&J: Company Snapshot
Table 79. J&J: Operating Segments
Table 80. J&J: Product Portfolio
Table 81. Novartis: Company Snapshot
Table 82. Novartis: Operating Segments
Table 83. Novartis: Product Portfolio
Table 84. Pfizer: Company Snapshot
Table 85. Pfizer: Operating Segments
Table 86. Pfizer: Product Portfolio
Table 87. Torrent: Company Snapshot
Table 88. Torrent: Product Portfolio
Table 89. Takeda: Company Snapshot
Table 90. Takeda: Operating Segments
Table 91. Takeda: Product Portfolio
Table 92. Teva: Company Snapshot
Table 93. Teva: Operating Segments
Table 94. Teva: Product Portfolio
List of Figures
Figure 01. Market Segmentation
Figure 02. Top Winning Strategies, by Year, 2015-2018*
Figure 03. Top Winning Strategies, by Development, 2015-2018* (%)
Figure 04. Top Winning Strategies, by Company, 2015-2018*
Figure 05. Top Investment Pockets
Figure 06. Market Share Analysis, 2020
Figure 07. Impact Analyses
Figure 08. Comparative Analysis of Aricept Market Revenue, by Country, 2020 & 2030 (%)
Figure 09. Comparative Analysis of Exelon Market Revenue, by Country, 2020 & 2030 (%)
Figure 10. Comparative Analysis of Namenda Market Revenue, by Country, 2020 & 2030 (%)
Figure 11. Comparative Analysis of Razadyne Market Revenue, by Country, 2020 & 2030 (%)
Figure 12. Comparative Analysis of Provigil Market Revenue, by Country, 2020 & 2030 (%)
Figure 13. Comparative Analysis of Ritalin Market Revenue, by Country, 2020 & 2030 (%)
Figure 14. Comparative Analysis of Adderall Market Revenue, by Country, 2020 & 2030 (%)
Figure 15. Comparative Analysis of Other Drugs Market Revenue, by Country, 2020 & 2030 (%)
Figure 16. Developmental Conditions Market, 2020-2023 ($ Million)
Figure 17. Neurodegenerative Disorders Market, 2020-2023 ($ Million)
Figure 18. Comparative Analysis of Disease Treatment Market Revenue, by Country, 2020 & 2030 (%)
Figure 19. Comparative Analysis of Cognitive and Memory Enhancer Drugs Market for Academic Performance Market, by Country, 2020 & 2030 (%)
Figure 20. Comparative Analysis of Cognitive and Memory Enhancer Drugs Market for Athletic Performance, by Country, 2020 & 2030 (%)
Figure 21. Comparative Analysis of Cognitive and Memory Enhancer Drugs Market for Other Applications, by Country, 2020 & 2030 (%)
Figure 22. Population Structure by Major Age Groups, Eu-28
Figure 23. Abbvie Inc: Net Sales, 2018–2020 ($ Million)
Figure 24. Abbvie Inc: Revenue Share by Segment, 2020 (%)
Figure 25. Abbvie Inc: Revenue Share Byregion, 2020 (%)
Figure 26. Biogen: Net Sales, 2018–2020 ($ Million)
Figure 27. Biogen: Revenue Share Byregion, 2020 (%)
Figure 28. J&J: Net Sales, 2018–2020 ($ Million)
Figure 29. J&J: Revenue Share by Segment, 2020 (%)
Figure 30. J&J: Revenue Share by Geography, 2020 (%)
Figure 31. Novartis: Net Sales, 2015–2017 ($ Million)
Figure 32. Novartis: Revenue Share by Segment, 2017 (%)
Figure 33. Novartis: Revenue Share by Geography, 2017 (%)
Figure 34. Pfizer: Net Sales, 2018–2020 ($ Million)
Figure 35. Pfizer: Revenue Share by Segment, 2020 (%)
Figure 36. Pfizer: Revenue Share by Geography, 2020 (%)
Figure 37Takeda: Net Sales, 2018–2020 ($ Million)
Figure 38. Takeda: Revenue Share by Segment, 2020 (%)
Figure 39. Takeda: Revenue Share by Geography, 2020 (%)
Figure 40. Teva: Net Sales, 2018–2020 ($ Million)
Figure 41. Teva: Revenue Share by Segment, 2020 (%)
Figure 42. Teva: Revenue Share by Geography, 2020 (%)

Executive Summary

According to a new report titled, “Cognitive and Memory Enhancer Drug Market by Product and Application: Global Opportunity Analysis and Industry Forecast, 2021–2030, the global cognitive and memory enhancer drug market size was valued at $5,079.86 million in 2020, and is projected to reach $8,689.74 million by 2030, registering a CAGR of 5.5% from 2021 to 2030.

Cognitive and memory enhancers are drugs or supplements that improve the cognitive functions such as memory and creativity among patients suffering from diseases such as neurological disorders as well as in healthy individuals.

The major factors that contribute to the market growth include growth in geriatric population, which is highly prone to neurological disorders such as Alzheimer’s. According to WHO, more than 46 million individuals live with dementia, which acts as an important factor influencing the growth of this market. In addition, many benefits offered by cognitive drugs such as improved memory and reasoning propel the market growth. Moreover, rise in adoption of cognitive drugs, owing to their benefits such as improved physical and mental performance, boosts the market growth. However, ethical issues related with the use of such drugs restrain the growth of this market.

COVID-19 Impact


The overall impact of COVID-19 is negative on the global cognitive and memory enhancer drugs market, owing to decline in the number of visits to hospitals and clinics for the treatment of neurodegenerative, and these drugs are mainly used in the treatment of neurodegenerative disorders, which led to decline in demand of cognitive & enhancer drugs market. However, with the ongoing vaccinations and decreasing cases of COVID-19, the studied market is expected to regain its full potential over the forecast period. in the future

The global cognitive and memory enhancer drug market is segmented into product, application, and region. Depending on product, the market is categorized into Aricept, Razadyne, Namenda, Exelon, Provigil, Ritalin, Adderall, and others. The applications covered in the study include disease treatment, education, sports, and others.

Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America accounted for the largest market share in the cognitive and memory enhancer drug market in 2020, and North America is expected to retain its dominance throughout the forecast period

By product, Aricept generated the maximum revenue in the global cognitive and memory enhancer drugs market in 2020, and is expected to dominate the market till 2030. The Provigil segment is expected to register the highest CAGR of 7.1 % during the forecast period, owing to increase in awareness among people toward improved physical performance.

By application, the disease treatment segment is expected to dominate the market in the future, owing to increase in the number of patients suffering from neurological diseases such as Alzheimer's. On the other hand, the education performance segment is estimated to exhibit a CAGR of 5.6% during the forecast period.

Key Findings Of The Cognitive And Memory Enhancer Drugs Market:

  • Aricept contributed for more than one-sixth share of the global cognitive and memory enhancer drugs market in 2016
  • Provigil is projected to grow at a significant CAGR of 71% from 2017 to 2023
  • Education segment is expected to grow at a significant CAGR of 56%
  • North America were the major shareholders in 2020, collectively accounting for more than one-third share of the global cognitive and memory enhancer drugs market
  • Region wise, North America garnered the largest revenue share in 2020, primarily due to high burden of Alzheimer’s disease coupled with increase in aging population, huge investment in research & development activities, and launch of new products in the region

The Asia-Pacific cognitive and memory enhancer drug market is projected to grow at the highest CAGR of 6.8% during the forecast period, owing to improvement in healthcare infrastructure and rise in expenditures in the emerging markets (such as India and China) to cater to the unmet medical needs.

The major companies profiled in the report are Pfizer Inc., Biogen., Allergan, Inc., Novartis AG, Torrent Pharmaceutical Inc, Johnson & Johnson, Takeda Pharmaceutical Company Limited, AlternaScript LLC, Cephalon, Inc. (Teva Pharmaceutical Industries Ltd.), and Ceretropic.

Companies Mentioned

  • AbbVie
  • Alterna Script LLC
  • Ceretropic
  • Biogen, Inc.
  • Johnson & Johnson
  • Novartis International AG
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Ltd.
  • Torrent Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd. (Cephalon Inc.).

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...